ResultsIQ › Latest results › Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited strategy deck summary
NSE: FREDUN · BSE: 539730
Strategy deck of 10 Jun 2025, summarised by AI from the filing.
Fredun Pharmaceuticals FY25 revenue ₹453.8 cr, EBITDA ₹55.1 cr, PAT ₹20.8 cr; Freossi Functional Food equipment to be commissioned by Q2 FY26.
Key takeaways
- FY25 revenue Revenue from operations ₹453.8 cr (FY24: ₹348.2 cr).
- FY25 EBITDA EBITDA ₹55.1 cr (FY24: ₹38.9 cr), margin 12.1% (FY24: 11.1%).
- FY25 PAT PAT ₹20.8 cr (FY24: ₹15.6 cr), margin 4.6% (FY24: 4.5%).
Fredun Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q1 FY27: Earnings call (13 Aug 2026)
- Q4 FY26: Earnings call (10 Jun 2026)
- Q3 FY26: Earnings call (12 Feb 2026)
- Q2 FY26: Earnings call (11 Nov 2025)
- Q1 FY26: Earnings call (1 Aug 2025)
- Other events: Call transcript (6 Jun 2026), Strategy deck (10 Jun 2025), Strategy deck (10 Jun 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.